Minireviews
Copyright ©The Author(s) 2019. Published by Baishideng Publishing Group Inc. All rights reserved.
World J Gastroenterol. Aug 7, 2019; 25(29): 3929-3940
Published online Aug 7, 2019. doi: 10.3748/wjg.v25.i29.3929
Hepatocellular carcinoma in the post-hepatitis C virus era: Should we change the paradigm?
Hadar Meringer, Oren Shibolet, Liat Deutsch
Hadar Meringer, Oren Shibolet, Liat Deutsch, Department of Gastroenterology and Hepatology, Tel Aviv Sourasky Medical Center and the Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv 6423906, Israel
Author contributions: All authors equally contributed to this paper with conception and design of the review, drafting, critical revision, editing, and approval of the final version.
Conflict-of-interest statement: No potential conflicts of interest. No financial support.
Open-Access: This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/
Corresponding author: Liat Deutsch, MD, Doctor, Department of Gastroenterology and Hepatology, Tel Aviv Sourasky Medical Center and the Sackler Faculty of Medicine, Tel Aviv University, 6 Weizmann St., Tel-Aviv 64239, Israel. liatml@tlvmc.gov.il
Telephone: +972-3-6974119 Fax: +972-3-6973422
Received: March 27, 2019
Peer-review started: March 28, 2019
First decision: April 16, 2019
Revised: May 29, 2019
Accepted: July 2, 2019
Article in press: July 3, 2019
Published online: August 7, 2019
Core Tip

Core tip: Hepatocellular carcinoma (HCC) is a common and deadly malignancy. One of the leading risk factors for HCC occurrence is liver cirrhosis secondary to hepatitis C virus (HCV) infection. Direct-acting antiviral therapy has revolutionized HCV eradication due to high sustained virologic response rates. However, early reports argued an increased risk of HCC occurrence and recurrence. Recently, non-alcoholic fatty liver disease has become the most common liver disorder in Western countries and a major cause of HCC. We aimed to review the changes in HCC management in the face of the changing epidemiology in the post-HCV era.